Effects of Dexmedetomidine on Delirium After Living Donor Renal Transplantation in Adult Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02509949|
Recruitment Status : Recruiting
First Posted : July 28, 2015
Last Update Posted : June 12, 2018
Delirium, an acute change in mental status, is a serious medical complication among hospitalized patients. Syndrome of delirium involves agitation, sleep disturbance, affective disorders and cognitive disruptions.
One vulnerable period for developing delirium is in the postoperative days. Postoperative delirium often initiates a cascade of adverse consequences including an increase in length of stay and hospital costs, and greater mortality. The investigators have observed that the incidence of postoperative delirium in patients after renal transplantation is about 20-30% in our hospital.
Several studies have revealed that dexmedetomidine, as a widely used sedative during anesthesia, can decrease the incidence of postoperative delirium after cardiac surgery. The investigators aim to examine whether administration of dexmedetomidine can reduce postoperative delirium after living donor renal transplantation in adult patients.
|Condition or disease||Intervention/treatment||Phase|
|Postoperative Delirium After Living Donor Renal Transplantation||Drug: Dexmedetomidine Drug: Saline||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Outcomes Assessor)|
|Study Start Date :||May 2015|
|Estimated Primary Completion Date :||September 2019|
Dexmedetomidine ivpump 0.2ug/kg/h during living donor renal transplantation.
Placebo Comparator: Saline
Saline ivpump 0.2ug/kg/h during living donor renal transplantation.
- Postoperative Delirium [ Time Frame: Postoperative day 1-7. ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02509949
|First Affiliated Hospital, Sun Yat-Sen University||Recruiting|
|Guangzhou, Guangdong, China, 510080|
|Contact: Tao Zhang, Master of Medicine 13580482938 firstname.lastname@example.org|